Panc02 Cells

The Panc02 cell line is a widely used murine model for studying pancreatic ductal adenocarcinoma (PDAC), the most common and aggressive form of pancreatic cancer. Panc02 cells were originally derived from a chemically induced pancreatic tumor in a C57BL/6 mouse. This cell line is highly relevant in preclinical research because it can be implanted orthotopically in syngeneic mice, mimicking the natural tumor environment and offering insights into the immune responses and therapeutic resistance mechanisms of PDAC. Research using Panc02 has provided significant insights into PDAC’s immunosuppressive microenvironment. One study showed that Panc02 tumors are heavily infiltrated by regulatory T cells (Tregs), which suppress the antitumor immune response. Treatment with low-dose gemcitabine was found to selectively deplete Tregs in Panc02 tumor-bearing mice, leading to an enhanced antitumor immune response and a modest increase in survival. This suggests that immunomodulation could be a promising therapeutic strategy for PDAC. In addition to immunotherapy studies, Panc02 has also been used to investigate necroptosis, a form of programmed cell death. Inhibition of Aurora Kinase A in Panc02 cells has been shown to induce necroptosis, which is important for overcoming resistance to apoptosis in PDAC. This provides a potential therapeutic approach to target apoptosis-resistant cancer cells by promoting non-apoptotic cell death pathways.